Track Novavax, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Novavax, Inc. NVAX · Stock Open Novavax, Inc. in new tab

8.53 USD
P/E
3.09
EPS
-0.52
P/B
-8.29
Beta
2.72
Target Price
14.11 USD
Novavax, Inc. logo

Novavax, Inc.

🧾 Earnings Recap – Q3 2026

Novavax fell 8.2% after earnings, despite raising its full-year revenue framework and improving expense guidance. The transcript points to limited near-term visibility beyond partner milestones: Sanofi’s U.S. phase III trial is targeted for 2027, while the company describes broader partnership and pipeline opportunities as still developing.

  • Sanofi’s European phase III flu/COVID combination trial triggered a $125 million milestone; Novavax expects another $75 million upon completion of manufacturing technology transfer in mid-2027.
  • Sanofi is targeting a U.S. phase III start in 2027 to support U.S. approval, leaving that opportunity dependent on future trial progress.
  • Sanofi began the 2026/2027 COVID season with Nuvaxovid in the U.S. and introduced it in select international markets; Takeda continues promoting it in Japan.
  • Novavax plans to enter the clinic with its C. diff vaccine candidate as early as next year.
  • Management said it raised its full-year revenue framework and improved expense guidance, but the transcript provides no revised figures.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
P/E3.09
EPS-0.52
Book Value-1.31
Price to Book-8.29
Debt/Equity607.28
% Insiders5.046%
Growth
Revenue Growth-0.03%
Earnings Growth-0.38%
Estimates
Forward P/E-21.19
Forward EPS-0.51
Target Mean Price14.11

DCF valuation

Model fair value for Novavax, Inc. (NVAX)
Result
Sign in to run the valuation for NVAX.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
9 analysts · consensus Buy · mean target 14.11 USD (low 7.00, high 25.00) · as of 10 Nov 2026
Low 7.00
Mean 14.11
High 25.00
Price 8.53
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Novavax, Inc. Logo Novavax, Inc. Analysis (NVAX)

United States Health Care Official Website Stock

Is Novavax, Inc. a good investment? Novavax, Inc. (NVAX) is currently trading at 8.53 USD. Market analysts have a consensus price target of 14.11 USD. This suggests a potential upside from current levels.

In terms of valuation, the stock trades at a P/E ratio of 3.09. This relatively low multiple may signal that Novavax, Inc. is undervalued compared to historical market norms.

Earnings Schedule: Novavax, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -0.51.

Investor FAQ

Does Novavax, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Novavax, Inc.?

Novavax, Inc. is classified as a Stock. You can compare it against 4 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -0.52.

Company Profile

Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine. It has license and collaboration agreements with Sanofi, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Serum Life Sciences Limited for the to develop, manufacture, and commercialize the COVID-19 vaccine. The company was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Exchange Ticker
FRA (Germany) NVV1.F
US6700024010
MEX (Mexico) NVAX.MX
NMS (United States) NVAX
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
May 10, 2019 1:20
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion